Skip to main content
Clinical Trials/NCT05185037
NCT05185037
Terminated
N/A

NIBP Algorithm Enhancements - MA_PM_NIBP Algorithm Enhancements_2021_11266

Philips Clinical & Medical Affairs Global1 site in 1 country17 target enrollmentMay 26, 2022

Overview

Phase
N/A
Intervention
Not specified
Conditions
Movement, Involuntary
Sponsor
Philips Clinical & Medical Affairs Global
Enrollment
17
Locations
1
Primary Endpoint
NIBP measurements with no technical alarms/INOPs
Status
Terminated
Last Updated
2 years ago

Overview

Brief Summary

The study intervention consists of a non-invasive blood pressure (NIBP) measurement device and cuff (FDA-cleared Philips IntelliVue X3 Rev. N.04 patient monitor) running a non-approved modified software containing an enhanced measurement algorithm for NIBP.

Detailed Description

The purpose of this study is to compare measurements of NIBP taken by the study device and measurements taken by the current FDA-approved algorithm included in Rev. N.0 software for the IntelliVue patient monitors during motion artifact in patients undergoing caesarian section deliveries under epidural anesthesia.

Registry
clinicaltrials.gov
Start Date
May 26, 2022
End Date
November 16, 2023
Last Updated
2 years ago
Study Type
Observational
Sex
Female

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Obstetric patient at Yale New Haven Hospital
  • Receiving epidural anesthesia
  • Age at least 18 years
  • Willing and able to provide informed consent in a Sponsor approved language
  • Willing and able to comply with study-related procedures
  • Priority classification II, III, or IV

Exclusion Criteria

  • Non-caesarian section deliveries
  • Ruptured uterus, prolonged fetal bradycardia, cord prolapse, or other emergent condition
  • Procedures under general anesthesia
  • Altered mental status
  • Currently participating in another clinical trial with any product, treatment and/or medication that clinically interferes with the study endpoint(s)
  • Priority classification I or V

Outcomes

Primary Outcomes

NIBP measurements with no technical alarms/INOPs

Time Frame: 1 Visit

The primary endpoint for this study is the rate of NIBP measurements that are valid based on evaluation by a panel of three independent, licensed physicians. Valid measurement will include no technical alarm (INOP).

NIBP measurements with Diastolic, Systolic, and mean pressure within a physiologically plausible range for the patient population, treatment, and medication

Time Frame: 1 Visit

The primary endpoint for this study is the rate of NIBP measurements that are valid based on evaluation by a panel of three independent, licensed physicians. Valid measurement will include Diastolic, Systolic, and mean pressures within a physiologically plausible range for the patient population, treatment and medication.

NIBP measurements with pulse pressure greater than 20% of the systolic blood pressure

Time Frame: 1 visit

The primary endpoint for this study is the rate of NIBP measurements that are valid based on evaluation by a panel of three independent, licensed physicians. Valid measurement will include pulse pressure greater than 20% of the systolic blood pressure.

Secondary Outcomes

  • Number of minutes between valid NIBP measurements compared to SoC(1 visit)

Study Sites (1)

Loading locations...

Similar Trials